Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
19.20
+0.36 (+1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
139,714
Open
18.84
Bid (Size)
18.10 (1)
Ask (Size)
20.50 (3)
Prev. Close
18.84
Today's Range
18.50 - 19.38
52wk Range
9.260 - 26.70
Shares Outstanding
25,167,365
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
April 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
April 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Performance
YTD
-12.57%
-12.57%
1 Month
-0.83%
-0.83%
3 Month
-1.64%
-1.64%
6 Month
+50.00%
+50.00%
1 Year
-18.51%
-18.51%
More News
Read More
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
April 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Recap: Castle Biosciences Q4 Earnings
February 28, 2024
Via
Benzinga
Earnings Preview For Castle Biosciences
February 27, 2024
Via
Benzinga
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
April 04, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Announces Updates to its Board of Directors
March 27, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
March 25, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
March 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
March 19, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
March 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
March 12, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
March 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
February 29, 2024
Via
Benzinga
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
February 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Via
Benzinga
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
February 26, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
February 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
January 18, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
January 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
January 09, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
January 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 25, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.